News

Generalized Anxiety Disorder Due for DSM-5 Makeover

Publish date: March 10, 2011

 

FROM THE ANNUAL PSYCHOPHARMACOLOGY REVIEW SPONSORED BY THE UNIVERSITY OF ARIZONA

Dr. Gelenberg disclosed that he serves as a consultant to several companies, including Eli Lilly, AstraZeneca, Wyeth, GlaxoSmithKline, ZARS Pharma, Jazz Pharmaceuticals, Lundbeck, Takeda, E-Research Technology, Dey Pharma, and PGxHealth.

Pages

Recommended Reading

U.K. Guidelines: Sertraline First for Generalized Anxiety Disorder
MDedge Family Medicine
ADHD Drug Approval Expanded
MDedge Family Medicine
U.S. Military Succeeds With Family-Based Resiliency Training
MDedge Family Medicine
Long-Acting Risperidone No Better Than Oral Antipsychotics
MDedge Family Medicine
Referenced EEGs May Guide Depression Treatment Better Than STAR*D Algorithm
MDedge Family Medicine
Rural Lung Cancer Survivors Face Higher Mental Distress
MDedge Family Medicine
Combo Beats Monotherapy in Major Depressive Disorder
MDedge Family Medicine
Worldwide Bipolar Disorder Prevalence Estimated at 2.4%
MDedge Family Medicine
Collaborative Depression Care Effective for Multiple Cardiac Diseases
MDedge Family Medicine
Psychiatric symptoms linked to a most unusual cause
MDedge Family Medicine